Job Watch

High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional)

Funding Opportunity RFA-AG-22-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the 2019 BSR NACA Review.

High-Priority Behavioral and Social Research Networks in Alzheimers Disease and Alzheimers Disease-Related Dementias (R24 Clinical Trial Optional)

Funding Opportunity RFA-AG-22-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure via networks for behavioral and social research on Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD); attract new researchers into behavioral and social research on AD/ADRD; infuse a focus on health disparities into AD/ADRD research; and address ongoing needs for harmonization and biomarker collection in large population panel studies to support AD/ADRD research as recommended by the 2019 BSR NACA Review.

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-21-061 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This funding opportunity will also provide a bridge to investigators who have completed their research training and may need extra time to develop a larger research project grant application.

Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)

Funding Opportunity PAR-21-176 from the NIH Guide for Grants and Contracts. This R21 funding opportunity encourages projects that test, in animals and/or humans, whether modifying electrophysiological patterns can improve cognitive, affective, or social processing. This R21 has a companion R01 (TEMP-10327). The proximal goal of this FOA (and its companion R01) is to encourage investigators to test whether modifying specific patterns of coordinated neural activity in vivo can improve cognitive, social, or affective processes. These studies should be based on a rational understanding of the role of specific neural activity rhythms in, for example, the routing of information among brain regions or in improving the ability of afferent information to affect local processing via coherence of underlying oscillatory activity.

Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)

Funding Opportunity PAR-21-175 from the NIH Guide for Grants and Contracts. This R01 funding opportunity encourages projects that test, in animals and/or humans, whether modifying electrophysiological patterns can improve cognitive, affective, or social processing. This R01 FOA is expected to have a companion R21 version. The proximal goal of this FOA (and its companion R21 version) is to encourage investigators to test whether modifying specific patterns of coordinated neural activity in vivo can improve cognitive, social, or affective processes. These studies should be based on a rational understanding of the role of specific neural activity rhythms in, for example, the routing of information among brain regions or in improving the ability of afferent information to affect local processing via coherence of underlying oscillatory activity.

Research on Bat Immunology (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-21-184 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research to characterize cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bat species with the potential for hosting zoonotic infections in humans.

Amid the pandemic, I learned to reflect on what really matters to me in a career

Publishing during the pandemic was a wake-up call for this Ph.D. student
Categories: Job Watch

Research Technologist I - Medical College of Wisconsin - Milwaukee, WI

Indeed.com - Bioinformatics - Wed, 2021-03-17 17:08
Microbiology, Genetics, Biology, Parasitology, Molecular Biology, Bioinformatics; Basic Science Building, Second Floor.
From Medical College of Wisconsin - Wed, 17 Mar 2021 21:08:06 GMT - View all Milwaukee, WI jobs
Categories: Job Watch

Bioinformatics Analyst I - Medical College of Wisconsin - Milwaukee, WI

Indeed.com - Bioinformatics - Wed, 2021-03-17 17:07
Adapts bioinformatics tools, visualization packages, and annotation resources for research projects to independently and accurately perform research analysis –…
From Medical College of Wisconsin - Wed, 17 Mar 2021 21:07:34 GMT - View all Milwaukee, WI jobs
Categories: Job Watch

Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-21-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious diseases, emerging infections, or immune-mediated diseases (that include allergy, autoimmunity, or immune reactions associated with transplantation henceforth referred to as "infectious or immune-mediated diseases") research continuum and align with the research mission of NIAID. As a part of the trans-NIAID Data Science (AI-DS) program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-21-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the enhancement and/or sustainment of high-value data science research software to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge across the immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on enhancement and/or sustaining operations and improving the user experience and availability of existing, widely adopted informatics tools and resources. This contrasts with exploratory (R21) and early-stage (U01) development efforts to generate these tools and resources that are supported by the companion FOA s.

Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-21-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOA s.

Paramount Recruitment: Cancer Genomics Data Scientst

New Scientist - Bioinformatics - Wed, 2021-03-17 12:00
Negotiable: Paramount Recruitment: Cancer Genomics Data Scientist London Genomics Data Scientists investigate and develop solutions to extract more information from the genome (ali London, England
Categories: Job Watch

The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional)

Funding Opportunity RFA-DK-21-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Proposals that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should propose a plan for integrating these discoveries with the present knowledge on established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8). In the long-term the goals of this initiative are to facilitate the development of better tools to monitor disease progression and treatment, and potentially to facilitate the development of personalized therapeutics.

Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-21-167 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not acceptable to this FOA.

Pages

Subscribe to Anil Jegga aggregator - Job Watch